| Trial ID: | L0085 |
| Source ID: | NCT03375788
|
| Associated Drug: |
Tesamorelin
|
| Title: |
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease|Obesity|Obesity, Abdominal|Liver Fat|Fatty Liver
|
| Interventions: |
Drug: Tesamorelin|Drug: Identical Placebo
|
| Outcome Measures: |
Liver Fat Content|NAFLD Activity Score|Post-prandial hepatic de novo lipogenesis|Non-high density lipoprotein (Non-HDL) Cholesterol|C-reactive protein|Fibrosis Score
|
| Sponsor/Collaborators: |
Massachusetts General Hospital
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
76
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
January 17, 2019
|
| Completion Date: |
September 30, 2024
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 30, 2021
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT03375788
|
